INOTREM
Inotrem , an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that the ASTONISH Independent Data Monitoring Committee (IDMC) completed the planned safety and efficacy assessment for futility of the company’s ongoing Phase IIB ASTONISH trial in septic shock patients.
The ASTONISH Phase IIB study aims at demonstrating safety and clinical efficacy of nangibotide in septic shock patients. It is a global, multicentric study conducted in 48 centers. Four hundred and fifty patients are planned to be enrolled in this study. The study compares the effect of nangibotide at two different doses versus standard of care. The futility analysis has been conducted on the first 225 patients enrolled. The primary endpoint for futility analysis was the delta SOFA score between the treatment groups and the standard of care/placebo group at day 5. A delta of 1 to 1.5 was observed in a previous Phase IIa trial in a subpopulation of septic shock patients with high concentration of soluble TREM-1, a mechanism-based biomarker. In addition, the ASTONISH study intends to validate a personalized medicine approach using soluble TREM-1 as potential companion diagnostic test to identify patients more likely to benefit from nangibotide treatment.
The IDMC’s decision marks a significant milestone for Inotrem’s development as it triggers the payment of the second tranche of €17 million of the Series B financing raised in 2020 from top-tier international investors.
“We are pleased with the IDMC's recommendation to continue the ASTONISH trial as it advances our understanding of the safety, tolerability and efficacy of nangibotide, our lead drug candidate, for septic shock patients. It is an important step toward establishing a potential new treatment for septic shock, a severe and often fatal condition for which there are currently no specific targeted therapies”, said Jean-Jacques Garaud, Executive Vice-President, Head of Scientific and Medical Affairs and Inotrem’s co-founder.
“We look forward to sharing updates from the ASTONISH trial in the coming months. The payment of this €17 million tranche strengthens our strategic ability to move towards the completion of our the septic shock program as well as the active development of our drug pipeline in chronic inflammatory conditions”, said Sven Zimmermann, CEO of Inotrem.
Septic shock is the ultimate complication of sepsis and currently constitutes a high unmet medical need. It represents a significant economic burden for the European healthcare system. Recent works have also emphasized the health economic impact of long term patients’ outcomes; indeed 30% of septic shock survivors are re-hospitalized in the three months following a first shock and between 20% and 30% have long term morbidities at twelve months. The incidence of septic shock is bound to increase as the population ages, leading to a rise in ICU admissions. Elderly patients are predisposed to septic shock due to existing co-morbidities, repeated and prolonged hospitalizations, reduced immunity, functional limitations and as well as the effects of aging itself. Europe is therefore poised to see a continuous rise in septic shock in the coming decades. We estimate that by 2025 the incidence of septic shock in Europe will be as high as 500,000 cases leading to 150,000 deaths per year. There is currently no specific therapy approved for this indication besides antibiotics and symptomatic treatment. Inotrem’s solution is based on a novel approach of immunomodulation which targets the TREM-1 pathway: a crucial mediator of the septic shock and has the potential to become the first mechanism-based treatment for septic shock.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapy for inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and COVID-19. In parallel, Inotrem has launched a program to develop new therapeutic modalities targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors. For more information please visit: www.inotrem.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005565/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AWS and HUMAIN Expand Partnership with NVIDIA AI Infrastructure and AWS AI Chip Deal to Drive Global AI Innovation19.11.2025 19:38:00 CET | Press release
Expanded partnership includes deployment of up to 150,000 AI accelerators including the latest NVIDIA GB300s AI infrastructure and AWS’s Trainium chips.Amazon Bedrock will provide customers access to best-in-class foundation models optimized across diverse, high performance AI chip infrastructures.AWS becomes HUMAIN’s preferred AI partner with AWS and HUMAIN collaborating to bring AI compute and services to customers worldwide. Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and HUMAIN, a Public Investment Fund (PIF) company delivering global full-stack AI solutions, announced today at the U.S.-Saudi Investment Forum their plans to provide, deploy and manage up to 150,000 AI accelerators in a data center facility known as an “AI Zone” in Riyadh. As part of the expanded partnership, AWS will become HUMAIN’s preferred AI partner globally, and the two companies will collaborate to bring AI compute and services from Saudi Arabia to customers worldwide. This pre
Luma AI Raises $900 Million Series C Led by HUMAIN And Partners on 2 Gigawatt AI Supercluster in Saudi Arabia19.11.2025 18:15:00 CET | Press release
New capital and compute infrastructure will accelerate Luma AI’s path towards Multimodal AGI – AI that can simulate reality and help humans in the physical world.HUMAIN to build Project Halo, one of the world’s largest AI compute clusters that will include the training of World Models, the next step in AI after LLMs - a potential trillion-dollar opportunity spanning entertainment, marketing/brands, education, world understanding, and robotics industries.Partnership includes HUMAIN Create, an initiative to build AI models trained on Arabic and regional data, helping enterprises and governments across MENA adopt culturally aligned AI. Luma AI, the frontier artificial intelligence company building multimodal AGI, today announced it has raised $900 million in Series C funding, led by HUMAIN, a PIF company delivering global full-stack AI solutions, with significant participation from AMD Ventures, and existing investors Andreessen Horowitz, Amplify Partners, and Matrix Partners. This press
Synthio Labs Raises $5 Million to Build the Voice AI Operating System for Life Sciences Customer Engagement19.11.2025 16:00:00 CET | Press release
Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, today announced that it has raised $5 million in seed funding. The round was led by Elevation Capital with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and several strategic angels from the global healthcare and AI ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119509940/en/ Rajashekar Vasantha (left), Supreet Deshpande (center), and Sahitya Sridhar (right), the founding team behind Synthio Labs’ voice-powered AI platform for pharma “We believe Synthio Labs is defining the next major Customer Engagement infrastructure for Life Sciences. Their Clinical-grade Voice AI platform unifies how pharma communicates - giving field teams a powerful voice companion, and giving physicians and patients instant, trusted, compliant answers 24/7. Pharma’s global Commercial and GTM foo
Torq Crushes EMEA Estimates With Record-Breaking Q3, Hitting 185% of Quarterly Target19.11.2025 15:00:00 CET | Press release
Torq Achieves 284%EMEA Customer Growth As It Signs Iconic Enterprises Including Virgin Atlantic, Kyocera, Siemens, and Zara Torq, the autonomous security operations leader, today announced it has exceeded Q3 EMEA revenue estimates, achieving 185% of its quarterly target. Torq is now firmly established as EMEA’s autonomous security operations platform of choice as enterprise goliaths continue joining its customer ranks, including Virgin Atlantic, Kyocera, Siemens, and Zara. Torq’s EMEA headcount grew 400% across 2025 to accommodate the exponentially increasing demand. “As worldwide momentum accelerates, Torq is doubling down on its EMEA investment by expanding operations, growing regional leadership, and strengthening our on-the-ground presence to fuel our next stage of growth,” said Ofer Smadari, CEO and co-founder, Torq. “Torq is now trusted by many of the world’s largest brands inside some of the most complex and sophisticated security operations centers. With new expansion into Germ
iConnections Launches Pipelines: A Powerful New Way for LPs and GPs to Turn Connections Into Real Momentum19.11.2025 15:00:00 CET | Press release
iConnections, the leading network for allocators and fund managers, today announced the launch of Pipelines, a new productivity and relationship-management tool built directly into the platform. Pipelines gives LPs and GPs a structured, visual, and purpose-built way to organize their outreach, nurture relationships, and drive their fundraising or investment processes forward—without relying on fragmented spreadsheets or generic CRMs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119021208/en/ Born from extensive feedback across the alternative investment ecosystem, Pipelines is designed to solve a common industry challenge: after a productive event or outreach cycle, promising conversations often lose momentum because there is no simple, tailored way to track next steps. “With Pipelines, users finally have a workflow that matches the way this industry actually operates,” said Douglas Melchior, VP of Product at iConnectio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom